Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

@article{Coles2012AlemtuzumabFP,
  title={Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial},
  author={Alasdair J. Coles and Cary Twyman and Douglas L. Arnold and Jeffrey A. Cohen and Christian Confavreux and Edward J. Fox and H. P. Hartung and Eva Kubala Havrdov{\'a} and Krzysztof W Selmaj and Howie Lawrence Weiner and Tamara Miller and Elizabeth Fisher and Rupert Sandbrink and Stephen L. Lake and David H. Margolin and Pedro Oyuela and Michael A. Panzara and D Alastair S Compston},
  journal={The Lancet},
  year={2012},
  volume={380},
  pages={1829-1839}
}

Figures and Tables from this paper

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
TLDR
Alemtuzumab was efficacious in a small cohort of relapsing-remitting MS patients of African descent over 8 years, and safety was consistent with the overall CARE-MS population, although the small sample size may have prevented the detection of known low-frequency adverse events.
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
TLDR
Trial results support alemtuzumab’s manageable, consistent safety profile in relapsing–remitting multiple sclerosis and recommend education, vigilance by physicians and patients, and monthly laboratory monitoring are recommended to maintain alemTuzumabs positive benefit:risk profile.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study
TLDR
Safety and neurological impact of alemtuzumab as last-line rescue therapy in aggressive multiple sclerosis patients, previously treated by Mitoxantrone, control aggressive RRMS despite previous use of MITOX is described.
Induction of disease remission with one cycle of alemtuzumab in relapsing–remitting MS
TLDR
The data suggests that induction of disease remission for some patients might occur following just one dose of alemtuzumab, which could support modification of the current therapy regimen.
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
TLDR
This study demonstrates the high efficacy of alemtuzumab over 6 years, with a similar safety profile between treatment groups; however, disability outcomes were less favorable versus alemTuzUMab-only patients.
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
TLDR
Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL in phase 3 trials in patients with relapsing-remitting multiple sclerosis.
Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis
TLDR
Alemtuzumab is an effective treatment for patients with relapsing-remitting multiple sclerosis, and has a generally acceptable tolerability profile, and was shown to be more effective than a current first-line treatment, subcutaneous interferon beta-1a, in decreasing relapse rate in treatment-naïve and previously treated patients and in decreasing disability progression in Previously treated patients.
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
TLDR
To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS to prevent disease activity, the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register was searched.
Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study
TLDR
Therapy switch was highly effective in reducing clinical and MRI surrogates of disease activity and was mainly well tolerated within one year of follow-up, indicating alemtuzumab constitutes a promising therapy in RRMS with refractory disease activity despite fingolimod treatment.
...
...

References

SHOWING 1-10 OF 38 REFERENCES
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
TLDR
In patients with early, relapsing-remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura.
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
TLDR
Class III evidence is provided that alemtuzumab is more effective than interferon β-1a in reducing relapses and disability in patients with RRMS in a long-term follow-up of a rater-blinded, randomized clinical trial with 59.5% of patients participating in the extended follow- up period.
Randomized, comparative study of interferon β-1a treatment regimens in MS
TLDR
IFNβ-1a 44 μg subcutaneously tiw was more effective than IFNβ -1a 30 μg IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
TLDR
Natalizumab added to interferon beta-1a was significantly more effective in patients with relapsing multiple sclerosis, and additional research is needed to elucidate the benefits and risks of this combination treatment.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
TLDR
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
TLDR
It is suggested that patients do not benefit in terms of disease outcome from switching between IFN beta preparations/dosing regimens, and benefits were consistently superior when IFNbeta was used as initial rather than follow-up therapy.
Defining interferon beta response status in multiple sclerosis patients.
TLDR
It was found that subgroups with high on-study relapse numbers had more disease progression, differences between responder subgroups were similar in the IFN-beta1a and placebo arms and Baseline characteristics failed to account for differential outcome.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
TLDR
This study shows that autoimmunity arose in those patients with greater T cell apoptosis and cell cycling in response to alemtuzumab-induced lymphocyte depletion, a phenomenon that is driven by higher levels of IL-21, and proposes that IL- 21 increases the stochastic opportunities for T cells to encounter self antigen and, hence, for autoIMmunity.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
TLDR
Lymphocyte counts recovered to LLN after a single course of alemtuzumab in approximately 8 months (B cells) and 3 years (T cell subsets), but usually did not recover to baseline values, however, this long lasting lymphopenia in patients with a previously normal immune system was not associated with an increased risk of serious opportunistic infection.
...
...